Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Accounts Payables (2018 - 2025)

Historic Accounts Payables for Precision Biosciences (DTIL) over the last 8 years, with Q3 2025 value amounting to $1.3 million.

  • Precision Biosciences' Accounts Payables rose 3987.47% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year increase of 3987.47%. This contributed to the annual value of $1.3 million for FY2024, which is 5579.51% down from last year.
  • According to the latest figures from Q3 2025, Precision Biosciences' Accounts Payables is $1.3 million, which was up 3987.47% from $1.1 million recorded in Q2 2025.
  • Precision Biosciences' 5-year Accounts Payables high stood at $3.0 million for Q4 2023, and its period low was $445000.0 during Q1 2021.
  • Its 5-year average for Accounts Payables is $983105.3, with a median of $924000.0 in 2025.
  • In the last 5 years, Precision Biosciences' Accounts Payables tumbled by 7480.18% in 2021 and then soared by 35451.76% in 2023.
  • Over the past 5 years, Precision Biosciences' Accounts Payables (Quarter) stood at $1.1 million in 2021, then plummeted by 42.92% to $653000.0 in 2022, then soared by 354.52% to $3.0 million in 2023, then crashed by 55.8% to $1.3 million in 2024, then grew by 2.13% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q3 2025, $1.1 million for Q2 2025, and $924000.0 during Q1 2025.